{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:52:57Z","timestamp":1789012377090,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260503"],"award-info":[{"award-number":["82260503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373254"],"award-info":[{"award-number":["82373254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Talent and Platform Program","award":["202305AF150136"],"award-info":[{"award-number":["202305AF150136"]}]},{"name":"Yunnan Provincial Department of Science and Technology Program","award":["202301AS070077"],"award-info":[{"award-number":["202301AS070077"]}]},{"name":"Sun Yat-Sen Memorial Hospital Clinical Research 5010 Program","award":["SYS-5010Z-202401"],"award-info":[{"award-number":["SYS-5010Z-202401"]}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2023A1515010258"],"award-info":[{"award-number":["2023A1515010258"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04074-4","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:39:12Z","timestamp":1749271152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Chenchen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengda","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peicong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"4","key":"4074_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK et al (2024) NCCN guidelines(R) insights: bladder cancer, version 3.2024. J Natl Compr Cancer Netw. 22(4):216\u2013225","journal-title":"J Natl Compr Cancer Netw."},{"issue":"1","key":"4074_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","volume":"25","author":"A Bamias","year":"2024","unstructured":"Bamias A, Davis ID, Galsky MD, Arranz JA, Kikuchi E, Grande E et al (2024) Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol 25(1):46\u201361","journal-title":"Lancet Oncol"},{"issue":"5","key":"4074_CR3","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70(5):404\u2013423","journal-title":"CA Cancer J Clin"},{"issue":"7457","key":"4074_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214\u2013218","journal-title":"Nature"},{"issue":"6","key":"4074_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899","journal-title":"Cell"},{"issue":"10","key":"4074_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider AK, Chevalier MF, Derre L (2019) The multifaceted immune regulation of bladder cancer. Nat Rev Urol 16(10):613\u2013630","journal-title":"Nat Rev Urol"},{"key":"4074_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph M, Enting D (2019) Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol 9:1270","journal-title":"Front Oncol"},{"issue":"19\u201320","key":"4074_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19\u201320):1267\u20131284","journal-title":"Genes Dev"},{"issue":"10064","key":"4074_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67\u201376","journal-title":"Lancet"},{"issue":"2","key":"4074_CR10","doi-asserted-by":"publisher","first-page":"e000419","DOI":"10.1136\/jitc-2019-000419","volume":"8","author":"J Hoffman-Censits","year":"2020","unstructured":"Hoffman-Censits J, Pal S, Kaiser C, Ding B, Bellmunt J (2020) Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. J Immunother Cancer 8(2):e000419","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4074_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J (2020) The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 20(11):662\u2013680","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4074_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341","journal-title":"Nat Rev Cancer"},{"issue":"2\u20133","key":"4074_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.mam.2013.01.001","volume":"34","author":"Y Kanai","year":"2013","unstructured":"Kanai Y, Clemencon B, Simonin A, Leuenberger M, Lochner M, Weisstanner M et al (2013) The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med 34(2\u20133):108\u2013120","journal-title":"Mol Aspects Med"},{"key":"4074_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fendo.2013.00165","volume":"4","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Danbolt NC (2013) GABA and glutamate transporters in brain. Front Endocrinol (Lausanne) 4:165","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"22","key":"4074_CR15","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.3390\/ijms20225674","volume":"20","author":"S Magi","year":"2019","unstructured":"Magi S, Piccirillo S, Amoroso S, Lariccia V (2019) Excitatory amino acid transporters (EAATs): glutamate transport and beyond. Int J Mol Sci 20(22):5674","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4074_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10142-022-00869-1","volume":"22","author":"K Kumar","year":"2022","unstructured":"Kumar K, Banerjee Dixit A, Tripathi M, Dubey V, Siraj F, Sharma MC et al (2022) Transcriptomic profiling of nonneoplastic cortical tissues reveals epileptogenic mechanisms in dysembryoplastic neuroepithelial tumors. Funct Integr Genomics 22(5):905\u2013917","journal-title":"Funct Integr Genomics"},{"issue":"23","key":"4074_CR17","doi-asserted-by":"publisher","first-page":"25496","DOI":"10.18632\/aging.203770","volume":"13","author":"X Zou","year":"2021","unstructured":"Zou X, Wei Y, Qi T, Wang X, Zuo W, Wang T et al (2021) A novel 6-gene signature derived from tumor-infiltrating T cells and neutrophils predicts survival of bladder urothelial carcinoma. Aging (Albany NY) 13(23):25496\u201325517","journal-title":"Aging (Albany NY)"},{"key":"4074_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2021.113085","volume":"229","author":"Y Yue","year":"2022","unstructured":"Yue Y, Deng P, Xiao H, Tan M, Wang H, Tian L et al (2022) N6-methyladenosine-mediated downregulation of miR-374c-5p promotes cadmium-induced cell proliferation and metastasis by targeting GRM3 in breast cancer cells. Ecotoxicol Environ Saf 229:113085","journal-title":"Ecotoxicol Environ Saf"},{"key":"4074_CR19","doi-asserted-by":"publisher","first-page":"1123841","DOI":"10.3389\/fimmu.2023.1123841","volume":"14","author":"S Koda","year":"2023","unstructured":"Koda S, Hu J, Ju X, Sun G, Shao S, Tang RX et al (2023) The role of glutamate receptors in the regulation of the tumor microenvironment. Front Immunol 14:1123841","journal-title":"Front Immunol"},{"key":"4074_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuint.2014.11.006","volume":"88","author":"GM Olsen","year":"2015","unstructured":"Olsen GM, Sonnewald U (2015) Glutamate: where does it come from and where does it go? Neurochem Int 88:47\u201352","journal-title":"Neurochem Int"},{"issue":"2","key":"4074_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","volume":"9","author":"NM Anderson","year":"2018","unstructured":"Anderson NM, Mucka P, Kern JG, Feng H (2018) The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell 9(2):216\u2013237","journal-title":"Protein Cell"},{"issue":"5","key":"4074_CR22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1158\/0008-5472.CAN-22-2045","volume":"83","author":"SJ Park","year":"2023","unstructured":"Park SJ, Yoo HC, Ahn E, Luo E, Kim Y, Sung Y et al (2023) Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer. Cancer Res 83(5):735\u2013752","journal-title":"Cancer Res"},{"issue":"10","key":"4074_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/jpm12101745","volume":"12","author":"V Bilim","year":"2022","unstructured":"Bilim V, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y (2022) Advanced bladder cancer: changing the treatment landscape. J Pers Med 12(10):1745","journal-title":"J Pers Med"},{"issue":"11","key":"4074_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100785","volume":"3","author":"J Hu","year":"2022","unstructured":"Hu J, Chen J, Ou Z, Chen H, Liu Z, Chen M et al (2022) Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med 3(11):100785","journal-title":"Cell Rep Med"},{"issue":"6477","key":"4074_CR25","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM (2020) Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367(6477):eaax0182","journal-title":"Science"},{"issue":"9","key":"4074_CR26","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM (2023) Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell 41(9):1551\u20131566","journal-title":"Cancer Cell"},{"issue":"12","key":"4074_CR27","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM et al (2020) Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 26(12):1839\u20131844","journal-title":"Nat Med"},{"issue":"4","key":"4074_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D et al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(4):525\u2013537","journal-title":"Lancet Oncol"},{"issue":"10212","key":"4074_CR29","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928","journal-title":"Lancet"},{"issue":"4","key":"4074_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/14737140.2022.2046466","volume":"22","author":"N Lobo","year":"2022","unstructured":"Lobo N, Martini A, Kamat AM (2022) Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 22(4):361\u2013370","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"4074_CR31","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol 17(11):1590\u20131598","journal-title":"Lancet Oncol"},{"issue":"4","key":"4074_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11427-020-1768-y","volume":"64","author":"Z Wu","year":"2021","unstructured":"Wu Z, Liu J, Dai R, Wu S (2021) Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 64(4):512\u2013533","journal-title":"Sci China Life Sci"},{"issue":"1","key":"4074_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 Challenges in Cancer Immunotherapy. Immunity 52(1):17\u201335","journal-title":"Immunity"},{"key":"4074_CR34","doi-asserted-by":"publisher","first-page":"102142","DOI":"10.1016\/j.ctrv.2020.102142","volume":"93","author":"M Rey-Cardenas","year":"2021","unstructured":"Rey-Cardenas M, Guerrero-Ramos F, Gomez de Liano Lista A, Carretero-Gonzalez A, Bote H, Herrera-Juarez M et al (2021) Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future. Cancer Treat Rev 93:102142","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"4074_CR35","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0006-2952(02)01218-2","volume":"64","author":"W Rzeski","year":"2002","unstructured":"Rzeski W, Ikonomidou C, Turski L (2002) Glutamate antagonists limit tumor growth. Biochem Pharmacol 64(8):1195\u20131200","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"4074_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmet.2020.06.010","volume":"32","author":"B Kelly","year":"2020","unstructured":"Kelly B, Pearce EL (2020) Amino assets: how amino acids support immunity. Cell Metab 32(2):154\u2013175","journal-title":"Cell Metab"},{"issue":"1\u20132","key":"4074_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2007.01.003","volume":"185","author":"R Pacheco","year":"2007","unstructured":"Pacheco R, Gallart T, Lluis C, Franco R (2007) Role of glutamate on T-cell mediated immunity. J Neuroimmunol 185(1\u20132):9\u201319","journal-title":"J Neuroimmunol"},{"issue":"10","key":"4074_CR38","doi-asserted-by":"publisher","first-page":"6695","DOI":"10.4049\/jimmunol.177.10.6695","volume":"177","author":"R Pacheco","year":"2006","unstructured":"Pacheco R, Oliva H, Martinez-Navio JM, Climent N, Ciruela F, Gatell JM et al (2006) Glutamate released by dendritic cells as a novel modulator of T cell activation. J Immunol 177(10):6695\u20136704","journal-title":"J Immunol"},{"issue":"7885","key":"4074_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","volume":"599","author":"B Zhang","year":"2021","unstructured":"Zhang B, Vogelzang A, Miyajima M, Sugiura Y, Wu Y, Chamoto K et al (2021) B cell-derived GABA elicits IL-10(+) macrophages to limit anti-tumour immunity. Nature 599(7885):471\u2013476","journal-title":"Nature"},{"issue":"1","key":"4074_CR40","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41392-022-01120-w","volume":"7","author":"Y Shi","year":"2022","unstructured":"Shi Y (2022) Linking B cell metabolism to immune regulation: the neurotransmitter GABA. Signal Transduct Target Ther 7(1):260","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4074_CR41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","volume":"55","author":"SK Seo","year":"2023","unstructured":"Seo SK, Kwon B (2023) Immune regulation through tryptophan metabolism. Exp Mol Med 55(7):1371\u20131379","journal-title":"Exp Mol Med"},{"issue":"11","key":"4074_CR42","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA (2022) The role of lipids in cancer progression and metastasis. Cell Metab 34(11):1675\u20131699","journal-title":"Cell Metab"},{"issue":"1","key":"4074_CR43","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ et al (2020) Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun 11(1):4011","journal-title":"Nat Commun"},{"key":"4074_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.629264","volume":"12","author":"W Hao","year":"2021","unstructured":"Hao W, Wu L, Cao L, Yu J, Ning L, Wang J et al (2021) Radioresistant nasopharyngeal carcinoma cells exhibited decreased cisplatin sensitivity by inducing SLC1A6 expression. Front Pharmacol 12:629264","journal-title":"Front Pharmacol"},{"issue":"2\u20133","key":"4074_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10295-015-1665-y","volume":"43","author":"MC Walker","year":"2016","unstructured":"Walker MC, van der Donk WA (2016) The many roles of glutamate in metabolism. J Ind Microbiol Biotechnol 43(2\u20133):419\u2013430","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"4","key":"4074_CR46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuint.2012.02.013","volume":"61","author":"NM Rowley","year":"2012","unstructured":"Rowley NM, Madsen KK, Schousboe A, Steve WH (2012) Glutamate and GABA synthesis, release, transport and metabolism as targets for seizure control. Neurochem Int 61(4):546\u2013558","journal-title":"Neurochem Int"},{"issue":"1","key":"4074_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1186\/s12885-023-11222-5","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Guo Q, Xing R (2023) Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma. BMC Cancer 23(1):727","journal-title":"BMC Cancer"},{"issue":"11","key":"4074_CR48","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.21037\/tcr-22-1653","volume":"11","author":"H Wang","year":"2022","unstructured":"Wang H, Dai Y, Wu X, Hu B, Wang Z, Yan M (2022) Multiomics analysis of ferroptosis-related molecular subtypes in muscle-invasive bladder cancer immunotherapy. Transl Cancer Res 11(11):4089\u20134104","journal-title":"Transl Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:37:36Z","timestamp":1757187456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4074"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04074-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the authors approved the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was approved by the Ethics Committees of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University (SYSKY-2024-1158-01). For animal study, the procedures for care and use of animals were approved by the Ethics Committee of the TopbiotechBiotechnology Co., Ltd (LFTOP-IACUC-2025-0003).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"240"}}